Hypokalemia secondary to capecitabine: a hidden toxicity?

BACKGROUND: Hyopkalemia is a listed toxicity in the capecitabine (Xeloda®; Roche, Nutley, NJ) package insert. However, the incidence and severity of this toxicity is not known. METHODS: We performed a retrospective evaluation of hypokalemia in 77 patients, who received capecitabine for gastrointesti...

Descripción completa

Detalles Bibliográficos
Autores principales: Saif, Muhammad Wasif, Fekrazad, Mohammad Houman, Ledbetter, Leslie, Diasio, Robert B
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936298/
https://www.ncbi.nlm.nih.gov/pubmed/18360625

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936298/
https://www.ncbi.nlm.nih.gov/pubmed/18360625

Ejemplares similares